USNewswire/ — The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and the Tau Consortium today announce a funding partnership to accelerate development of novel positron emission tomography (PET) imaging tracers for the detection of the alpha-synuclein and tau proteins in the living brain.
Several neurodegenerative diseases — Parkinson’s disease, Lewy body dementia, multiple system atrophy, progressive supranuclear palsy and frontotemporal dementia, among others — involve the aggregation of alpha-synuclein and/or tau. Tools to detect the location and abundance of these proteins would improve clinical care and speed drug development by allowing earlier and more definitive diagnosis, more precise trial subject selection, and more efficient and conclusive therapeutic impact assessment.
“The ability to monitor disease, potentially even before symptom onset, would revolutionize the patient care experience and the pace of drug development,” said MJFF CEO Todd Sherer, PhD. “This partnership with the Tau Consortium will bring us closer to that goal.”
Patrick Brannelly, Program Director of the Tau Consortium, said, “The process of developing a new PET tracer is challenging, complex and iterative. It makes sense for nonprofits and industry to pool their resources in pursuit of success.”
Under this new partnership, the Tau Consortium and MJFF will convene and co-fund a team of leading scientists who will closely coordinate their development of compounds that may bind to alpha-synuclein or tau. Gil Rabinovici, MD, of the University of California, San Francisco, will direct the initiative. The inaugural grantees are Chester Mathis, PhD, Director of the University of Pittsburgh PET Facility, and Neil Vasdev, PhD, Co-founder of MedChem Imaging LLC.
“It’s an honor to work alongside these outstanding investigators and as the director of such an important initiative,” said Dr. Rabinovici. “Presently, these protein aggregates can be measured only at autopsy. Our field needs better tools to enable earlier intervention with potentially disease-modifying treatments.”
PET tracers to evaluate protein load in the living brain would allow clinicians and researchers to diagnose people in prodromal or early disease stage, leading care decisions and earlier intervention with potentially disease-modifying treatments. A hypothesis for why some drugs in testing fail is that study participants are too advanced in the disease; an imaging tracer would allow testing in earlier-stage volunteers. Additionally, data from PET tracers would allow researchers to evaluate the biological impact of their candidate drugs.
Given the importance of this technology, MJFF and the Tau Consortium have invested significantly in this area of research. For example, The Michael J. Fox Foundation is supporting other projects pursuing an alpha-synuclein PET tracer and last year announced a $2M prize to the first group to develop a viable selective tracer and agree to make the tool available broadly.
About The Michael J. Fox Foundation for Parkinson’s Research
As the world’s largest nonprofit funder of Parkinson’s research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson’s disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson’s patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than $700 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson’s research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson’s disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson’s awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world. For more information, visit www.michaeljfox.org.
About the Tau Consortium
The Tau Consortium is an innovative medical research program that is operated under the auspices of the Rainwater Charitable Foundation. The Consortium commissions world-class basic research and drug discovery to treat and prevent progressive supranuclear palsy (PSP) and other tauopathies. The Tau Consortium acts with urgency and with patients in mind. It ensures that its members work collaboratively and engage with partners who can accelerate their progress. Since founding the Tau Consortium in 2009, the Rainwater Charitable Foundation has committed nearly $100 million to the program. There are currently five treatments in early stage human trials for PSP as a result of the Rainwater family’s funding. Please visit http://tauconsortium.org for more information.
SOURCE The Michael J. Fox Foundation